ClinicalTrials.gg
Not yet recruitingNCT07943949Updated Nov 17, 2026

Effect of a Comprehensive Package Based on Multimarker Blood-based Point-of-care Testing on Antibiotic Prescribing for Acute Respiratory Tract Infections at Village Clinics in China

An interventional study of CBC&CRP&SAA POCT in Antibiotic Prescribing for Acute Respiratory-tract Infections, sponsored by Huazhong University of Science and Technology. Not yet recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70,000
Allocation
Randomized
Sex
All
01

Study summary

This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China.

Read the detailed description

This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China. We will conduct the trial over six months in 80 village clinics across 10 townships in Xiantao and Jingmen, Hubei Province (with 5 townships in Xiantao and 5 in Jingmen). Village clinics will be randomly assigned in a 1:1 ratio to either the intervention or control group, stratified by city and township. A comprehensive intervention package based on multimarker blood-based POCT will be implemented in 40 village clinics within the intervention group. In addition to equipping these clinics with POCT devices, we will provide systematic guidance through a combination of centralised training sessions and the distribution of training manuals. The training will focus on the standardised operation of POCT and clinical pathways to guide antibiotic prescriptions for the treatment of ARIs based on test results. We will provide patient education through leaflets, primarily aimed at helping rural patients understand how multimarker blood-based POCT can aid in their diagnosis and treatment, thereby improving patient acceptance. The control group will undergo diagnosis and treatment in accordance with routine care procedures, without any intervention.

02

Conditions studied

  • Antibiotic Prescribing for Acute Respiratory-tract Infections

Keywords

  • Point-of-care testing
  • Acute respiratory tract infections
  • Village clinics
  • Antibiotic prescription
03

In context

Lead sponsor

Huazhong University of Science and Technology is the lead sponsor of 248 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility criteria for clusters. Village clinics will be eligible if they have not previously participated in a POCT-guided antibiotic prescribing programme, record more than 2,000 outpatient visits annually, manage an average of at least 10 patients with ARIs per week, and have licensed prescribers. Eligibility will be verified using prescription records from the preceding year obtained from the information management departments of the local health authorities.

Eligibility criteria for participants. The target population comprises patients of all ages who either (1) have been diagnosed by village doctors with an ARI, including upper or lower respiratory tract infections; or (2) present with at least one acute respiratory symptom or sign, such as cough, sore throat, rhinitis (nasal congestion, sneezing, or rhinorrhoea), wheezing, or abnormal findings on auscultation. Patients diagnosed with non-respiratory conditions and those whom village doctors consider require referral to a higher-level healthcare facility based on their clinical presentation will be excluded.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70,000 participants (estimated)

Study arms

  • No intervention
    Control group

    The control group will not have any intervention, as the control (usual care)

  • Experimental
    Intervention group

    All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs.

    Diagnostic Test: CBC&CRP&SAA POCT

Interventions

  • Diagnostic testCBC&CRP&SAA POCT

    All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs. Each intervention clinic will receive a concise, easy-to-follow decision flowchart summarising the prespecified thresholds for selected CBC parameters, CRP, and SAA. Following randomisation, all village doctors in the intervention group will receive standardised centralised training. The research team will also provide each village clinic in the intervention group with a guidance manual on appropriate antibiotic use for ARIs supported by combined CBC, CRP, and SAA POCT. Plain-language, non-technical information leaflets will be distributed at all village clinics in the intervention group.

06

What researchers measure

Primary outcomes

  1. The primary outcome will be a binary indicator of whether at least one antibiotic is prescribed by the village doctor during an eligible index consultation for an ARI.

    An index consultation is defined as an ARI-related consultation by a patient who has not had any recorded ARI consultations at the same village clinic in the preceding 14 days. This measure aims to capture the overall effect of the POCT-supported multicomponent intervention on antibiotic prescribing decisions for ARIs. Since most ARIs are viral and self-limiting, a lower prescribing proportion-provided that patient recovery and safety are not compromised-would indicate more selective use of antibiotics by village doctors. This endpoint is particularly suitable for research in village clinics in China because prescriptions are now routinely recorded electronically rather than solely on paper. These digital records enable standardised data extraction and auditing, thereby supporting the completeness and traceability of outcome ascertainment.

    Time frame: The 6-month intervention

Secondary outcomes

  1. The proportion of eligible index consultations in which two or more antibiotics are prescribed

    Time frame: The 6-month intervention

  2. The proportion in which at least one antibiotic is administered intravenously

    Time frame: The 6-month intervention

  3. The proportion in which at least one traditional Chinese medicine is prescribed

    Time frame: The 6-month intervention

  4. The medication cost per eligible index consultation

    Time frame: The 6-month intervention

  5. The total cost per eligible index consultation

    Time frame: The 6-month intervention

Other outcomes

  1. The proportion of patients who initiate any additional antibiotic during the 14 days following an eligible index consultation for an ARI will be assessed in a randomly selected subsample

    Time frame: The 6-month intervention

  2. The principal safety outcome will be the proportion of patients admitted to any hospital within the corresponding study city for an ARI or sepsis within 30 days after the index consultation.

    Time frame: The 6-month intervention

  3. In the randomly selected patient subsample, we will also assess time to recovery from ARI symptoms through the 14-day telephone follow-up.

    Time frame: From the index consultation to the end of treatment at 2 weeks

07

Study locations

2 sites
  • 40 Village Clinics
    Jingmen, Hubei 448000, China
  • 40 Village Clinics
    Xiantao, Hubei 433000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Jun 15, 2027
CompletionEst.
Jul 15, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943949
Responsible party
Xiaoxv Yin, PhD (Professor and Head of Social Medicne and Health Management Department, Huazhong University of Science and Technology) — Principal investigator
First posted
Nov 17, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Jun 15, 2027 (estimated)
Completion
Jul 15, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Xiaoxv Yin
Contact
yxx@hust.edu.cn
+86 13871187781
Minzhi Xu
Contact
619581384@qq.com
+86 18737357795

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion